person · Reporting owner
Shah Keeren Rameshchandra
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OKYO Pharma LtdOKYO · Entity 6916 | Chief Financial Officer | June 08, 2026 | June 10, 2026 |
| Tiziana Life Sciences LtdTLSA · Entity 6639 | CHIEF OPERATING & FIN. OFFICER | March 18, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OKYO Pharma Ltd
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2036-06-08 | Direct | 544,819 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 40,000 · Balance 544,819 |
Tiziana Life Sciences Ltd
Report date March 18, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 2,500 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,500 |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2030-05-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2030-05-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2030-05-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.88 · Expires 2030-05-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2033-03-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2033-03-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2033-03-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2033-03-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2034-03-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2034-03-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2034-03-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-10-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-10-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-10-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-10-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2035-09-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2035-09-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2035-09-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance Not disclosed |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2035-09-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance Not disclosed |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 21:00 UTC | OKYO Pharma Ltd OKYO · Entity 6916 | GrantOption · Derivative | 40,000 | $1.85 Strike: $1.85 | $74,000.00 |
DisclosureSEC source: 0001493152-26-028131 · ownership.xml · derivative · entry 1 Shah Keeren Rameshchandra · CIK 0002125071 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,819 Underlying: Common Shares · 40,000 shares Expires 2036-06-08 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.